Clincosm LogoSign in Get a demo

primary immunodeficiency diseases (pid)

Showing 1 - 18 of 18
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • No Intervention
  • (no location specified)
Nov 21, 2023

Primary Immunodeficiency Diseases (PID) Trial (TAK-881)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • TAK-881
  • (no location specified)
Oct 4, 2023

Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety

Recruiting
  • Primary Immunodeficiency Diseases (PID)
  • Moscow, Russian Federation
    Dmitry Rogachev National Research Center of Pediatric Hematology
Aug 8, 2023

Primary Immunodeficiency Diseases (PID) Trial (TAK-881, HYQVIA)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • TAK-881
  • HYQVIA
  • (no location specified)
Feb 23, 2023

Primary Immunodeficiency Diseases (PID) Trial in United States (HYQVIA, GAMMAGARD LIQUID)

Completed
  • Primary Immunodeficiency Diseases (PID)
  • HYQVIA
  • GAMMAGARD LIQUID
  • Birmingham, Alabama
  • +18 more
Sep 28, 2022

Primary Immunodeficiency Diseases (PID) Trial (TAK-771)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • (no location specified)
Aug 22, 2022

Primary Immunodeficiency Diseases (PID) Trial in Japan (Immune Globulin Intravenous (IGIV), Immune Globulin Subcutaneous, 20%

Completed
  • Primary Immunodeficiency Diseases (PID)
  • Immune Globulin Intravenous (IGIV)
  • Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)
  • Nagoya-shi, Aichi, Japan
  • +7 more
Feb 23, 2022

Study on the Long-Term Safety of HYQVIA (Global)

Completed
  • Primary Immunodeficiency Diseases (PID)
  • HYQVIA
  • Bakersfield, California
  • +29 more
Jan 20, 2022

Primary Immunodeficiency Diseases (PID), Agammaglobulinemia, Hypogammaglobulinemia Trial in Finland, Sweden (Immune Globulin

Completed
  • Primary Immunodeficiency Diseases (PID)
  • +2 more
  • Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution
  • Gammagard S/D (Solvent/Detergent)
  • Tampere, Finland
  • +5 more
Aug 22, 2021

Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome Trial in United States (Immune

Completed
  • Primary Immunodeficiency Diseases (PID)
  • +2 more
  • Immune Globulin Intravenous (Human), 10%
  • Los Angeles, California
  • +10 more
Aug 22, 2021

Primary Immunodeficiency Diseases (PID) Trial in Canada, United States (Immune Globulin Intravenous (Human), 10% Solution,

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • Immune Globulin Intravenous (Human), 10% Solution
  • Immune Globulin Subcutaneous (Human), 20% Solution
  • Irvine, California
  • +17 more
Jun 30, 2021

Primary Immunodeficiency Diseases (PID) Trial in United States (Immune Globulin Intravenous (Human), 10%)

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • Immune Globulin Intravenous (Human), 10%
  • Los Angeles, California
  • +8 more
Apr 29, 2021

Primary Immunodeficiency Diseases (PID) Trial in Canada, United States (Recombinant human hyaluronidase (rHuPH20)+ immune

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
  • Cypress, California
  • +13 more
Apr 30, 2021

Primary Immunodeficiency Diseases (PID) Trial in United States (Immune Globulin Infusion (Human), 10%, Recombinant human

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • Immune Globulin Infusion (Human), 10%
  • Recombinant human hyaluronidase
  • Irvine, California
  • +9 more
Apr 30, 2021

Primary Immunodeficiency Diseases (PID) Trial in United States (SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC,

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)
  • +2 more
  • Cypress, California
  • +10 more
Apr 30, 2021

Primary Immunodeficiency Diseases (PID) Trial in Worldwide (Immune Globulin Subcutaneous (Human), 20%, Immune Globulin

Completed
  • Primary Immunodeficiency Diseases (PID)
  • Immune Globulin Subcutaneous (Human), 20%
  • +2 more
  • Vienna, Austria
  • +11 more
Apr 30, 2021

Primary Immunodeficiency Diseases (PID) Trial in Centennial, North Palm Beach, Dallas (Recombinant human hyaluronidase + immune

Completed
  • Primary Immunodeficiency Diseases (PID)
  • Recombinant human hyaluronidase + immune globulin intravenous
  • Centennial, Colorado
  • +2 more
Apr 30, 2021

Real-world CANadian CUvitru Non-Interventional Study in Subjects

Completed
  • Primary Immunodeficiency Diseases (PID)
  • CUVITRU
  • Hamilton, Ontario, Canada
  • +2 more
Mar 3, 2021